linjc16/ctgov huggingface dataset:
Pancreatic Cancer Models Developed From EUS Guided Biopsy Tissue

Study Overview
=================
Brief Summary
-----------------
Pancreatic cancer is a very aggressive cancer. Over the past 40 years there has not been much progress made in reducing deaths from this cancer. Recently, new models of pancreatic cancers have been generated from mouse and human tissues. These models have used larger pieces of tissues taken from surgical removal of pancreatic cancers. The purpose of this study is to determine whether these new pancreatic cancer models can be generated from the small biopsies we take to make the diagnosis of the pancreatic mass.

Detailed Description
-----------------
The Endoscopic Ultrasound guided pancreatic biopsy tissue collected for only research purposes will be used to generate organoids in a in-vivo and in-vitro setting. The development of these methods may help scientists identify new treatments for pancreatic cancer and to potentially develop more personalized approaches to treating pancreatic cancer.

Official Title
-----------------
EUS-guided Biopsy of Pancreatic Mass Lesions for Developing Patient -Derived Cancer Models

Conditions
-----------------
Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Cyst

Intervention / Treatment
-----------------
* Procedure: Biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Patients who are scheduled for an EUS-FNB of pancreatic mass(es) suspicious for pancreatic ductal adenocarcinoma performed by a member of the Stony Brook Interventional Endoscopy Section of the Division of Gastroenterology and Hepatology Age ≥ 18 years Literate and able/willing to provide informed consent for participation in research. Exclusion Criteria: Age < 18 years Not literate or unable/unwilling to provide informed consent for EUS-FNB research biopsies Pregnancy as determined by serum or urine HCG test performed as standard of clinical care for all women of childbearing age and documented on subjects' electronic medical record

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Biopsy|Two extra EUS guided pancreatic biopsies collected for only research purposes.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful generation of pancreatic organoids | The two extra biopsy tissues collected for only research purposes will be used to generate pancreatic organoids in a in-vivo as well as in-vitro setting. | 6 years |
Ultrasound Guided Transversus Abdominis Plane Block With Ropivacaine vs Placebo for Abdominal Hysterectomy: a Double-blinded, Randomized Clinical Trial

Study Overview
=================
Brief Summary
-----------------
A Prospective double-blinded randomized clinical trial to test the effect of transversus abdominis plane block on postoperative pain and opoid consumption after abdominal hysterectomy. Two groups of each 24 patients. All patients are given general anesthesia. The patients are randomized to have a ultrasound guided bilateral transversus abdominis plane block with either 2 x 20 ml 0,75 % ropivacaine or 2 x 20 ml of 0,9 saline. All patients are provided with a PCA for self administration of morphine. Pain score on visual analog scale, nausea and vomiting are monitored at 1, 2, 4, 6, 8 and 24 hours postoperatively as well as the total consumption of morphine after 24 hours.

Official Title
-----------------
Ultrasound Guided Transversus Abdominis Plane Block With Ropivacaine vs Placebo for Abdominal Hysterectomy: a Double-blinded, Randomized Clinical Trial

Conditions
-----------------
Postoperative Pain and Postoperative Morphine Consumption After Abdominal Hysterectomy

Intervention / Treatment
-----------------
* Procedure: TAP Block Ropivacaine 0,75 %
* Procedure: TAP Block Saline 0,9 %


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Assigned to elective abdominal hysterectomy Must be able to understand and speak danish Must be able to give verbal and written consent Exclusion Criteria: Abuse of alcohol or medicin Daily treatment with opoids or glucocorticoids Allergy towards any kind of localanesthetic drug Intolerance toward morphine Psychiatric desease Age below 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TAP Block Ropivacaine 0,75 %<br>Bilateral Transversus Abdominis Plane Block with 2 x 20 ml Ropivacaine 0,75 % | Procedure: TAP Block Ropivacaine 0,75 %<br> <br> |
| Placebo Comparator: TAP Block Saline 0,9 %<br>Bilateral Transversus abdominis plane block with 2 x 20 ml Saline 0,9 % | Procedure: TAP Block Saline 0,9 %<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total morphine consumption during first 24 hours postoperatively |  | At 24 hours postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative pain by visual analog scale at | Monitored at 1, 2, 4, 6, 8 and 24 hours postoperatively by one of the investigators at rest, when coughing and when walking | Monitored at 1, 2, 4, 6, 8 and 24 hours postoperatively |
Surgicel® Fibrillar for Delayed Bleeding After ESD

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess the effect of Surgicel® Fibrillar as adjuvant treatment to H2RA on preventing ulcer bleeding after ESD for gastric epithelial tumors

Detailed Description
-----------------
Patient (1) Inclusion: Diagnosed as gastric dysplasia or early gastric cancer Scheduled for ESD (2) Exclusion: Coagulopathy- liver cirrhosis, thrombocytopenia Anti-platelet agents Method (1) Study group: combination with Surgicel® Fibrillar and H2RA (2) Control group: monotherapy with PPI 3. Sample size : 157 4. Result Primary endpoint: rate of delayed bleeding after ESD Secondary endpoint: follow-up hemoglobin after ESD

Official Title
-----------------
Surgicel® (Fibrillar) for Preventing Delayed Bleeding After ESD in Stomach: A Prospective Randomized Study

Conditions
-----------------
Benign Neoplasm of Stomach, Malignant Neoplasm of Stomach

Intervention / Treatment
-----------------
* Other: PPI
* Other: H2RA and surgicel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ESD for gastric dysplasia or early gastric cancer Exclusion Criteria: Coagulopathy: liver cirrhosis, thrombocytopenia Anti-platelet agents

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: combination therapy of H2RA and surgicel<br>H2RA and surgicel | Other: H2RA and surgicel<br>* combination therapy of H2RA and surgicel<br>|
| Experimental: Monotherapy of PPI<br>PPI | Other: PPI<br>* monotherapy of PPI<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Delayed bleeding rate after ESD |  | 1 year |
Heating Precondition of Streamlined Liner of the Pharynx Airway Decrease the Incidence of Sore Throat

Study Overview
=================
Brief Summary
-----------------
The effect of heating precondition of streamlined liner of the pharynx airway (SLIPA) on respiratory mechanics and sore throat was investigated.

Conditions
-----------------
Complication of Artificial Airway

Intervention / Treatment
-----------------
* Other: heating precondition


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hysteroscopic surgery General anesthesia Exclusion Criteria: Upper respiratory disease Communication disfunction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: heating precondition<br>The mean maximum sealing pressure, gas leakage, gastric distension, postoperative sore throat and other complication were compared between heating precondition group and control group. | Other: heating precondition<br>* The streamlined liner of the pharynx airway (SLIPA) was heated 2 hours before use.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oropharyngeal leak pressure |  | 5 minutes | 
| postoperative sore throat |  | 60 minutes |
Effect of Coaching on Mid-Career Physician Well-Being, Job Satisfaction, and Fulfillment

Study Overview
=================
Brief Summary
-----------------
The study will assess the effect of individualized professional coaching for mid-career family medicine and general internal medicine physicians on burnout, job satisfaction, and professional fulfillment.

Official Title
-----------------
RCT: Effect of Coaching on Mid-Career Physician Well-Being, Job Satisfaction, and Fulfillment

Conditions
-----------------
Burnout, Professional

Intervention / Treatment
-----------------
* Behavioral: Professional Coaching


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria General internal medicine and family physicians In practice for 5-30 years Exclusion Criteria: physicians who specialize in areas other than general internal medicine and family medicine physicians who have been in practice less than 5 years or more than 30 years

Ages Eligible for Study
-----------------
Minimum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Immediate Coaching Intervention<br>Immediate Coaching Intervention arm will receive professional coaching | Behavioral: Professional Coaching<br>* Professional, individualized coaching<br>|
| Active Comparator: Control/Delayed Coaching Intervention<br>Participants randomized to the Control/Delayed Coaching will receive no intervention for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions | Behavioral: Professional Coaching<br>* Professional, individualized coaching<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Maslach Burnout Inventory score |  | 6 month | 
| Change in Physician Job Satisfaction Scale score |  | 6 month | 
| change in Empowerment at Work Scale score |  | 6 month | 
| change in Utrecht Work Engagement score |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Maslach Burnout Inventory score |  | 12 month | 
| Change in Physician Job Satisfaction Scale score |  | 12 months | 
| change in Empowerment at Work Scale score |  | 12 months | 
| change in Utrecht Work Engagement score |  | 12 months |
Long Term Excess Mortality of Acute Myocardial Infarction in Patients With and Without Diabetes: A Population-based Cohort Study

Study Overview
=================
Brief Summary
-----------------
Diabetes is key risk factor for death following acute myocardial infarction. However, the long-term excess risk of death associated with diabetes following acute myocardial infarction not known. Investigators aimed to determine the long-term excess risk of death associated with diabetes among patients with ST-elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) after adjustment for multimorbidity, risk factors and cardiac treatments.

Conditions
-----------------
Effect of Diabetes on Long Term Excess Mortality Following Acute Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute myocardial infarction Both sex 18 years Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ST-elevation myocardial infarction (STEMI)<br> | |
| non-ST-elevation myocardial infarction (NSTEMI)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Long term excess mortality |  | 8 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes, ST-elevation myocardial infarction (STEMI), non-STEMI, Excess mortality, Relative survival
Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes?

Study Overview
=================
Brief Summary
-----------------
Baclofen is a drug that reduces the muscle stiffness. In disabled children that have very stiff muscles, the stiffness and secondary changes in the joints may cause discomfort and pain. In this study we will check if treatment with Baclofen reduces pain in disabled children with stiff muscles.

Conditions
-----------------
Cerebral Palsy

Intervention / Treatment
-----------------
* Drug: oral baclofen + placebo
* Drug: placebo + oral baclofen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cerebral palsy nursing homes children ages 1-18 years spastic quadriplegia Exclusion Criteria: active epilepsy severe truncal hypotonia

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: group a<br>Baclofen followed by Placebo | Drug: oral baclofen + placebo<br>* Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo. For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks. For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days. Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur.<br>|
| Experimental: group b<br>Placebo followed by Baclofen | Drug: placebo + oral baclofen<br>* Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| care and comport questionnaires |  | 28 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nursing homes, children, ages 1-18 years, spastic quadriplegia
Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
This observational study is conducted in Europe. The trial aims to observe the incidence of serious adverse drug reactions in children and adolescents with type 1 diabetes during Levemir® treatment.

Official Title
-----------------
Safety of Levemir® (Insulin Detemir) Treatment in Children and Adolescents With Type 1 Diabetes (PREDICTIVE™ - Youth)

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: insulin detemir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent obtained prior to any trial-related activities Any patient with diabetes type 1 is eligible for the study, including newly The selection of the patients will be at the discretion of the individual physician Exclusion Criteria: Type 2 diabetes Currently treated with Levemir®

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br> | Drug: insulin detemir<br>* No extra intervention, only normal clinical practise for treatment of type 1 diabetes<br>* Other names: Levemir®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of serious adverse drug reactions, including major hypoglycaemic events |  | after 6 month treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of all hypoglycaemic events |  | after 6 month treatment | 
| Number of adverse drug reactions |  | after 6 month treatment | 
| BMI changes |  | after 6 month treatment | 
| HbA1c |  | after 6 month treatment | 
| Variability in FPG (Fasting Plasma Glucose) |  | after 6 month treatment |
Pressure Gradient vs. Flow Relationships in Patients With Symptomatic Valvular Aortic Stenosis

Study Overview
=================
Brief Summary
-----------------
The objective of the present study is to investigate to hemodynamic profile at rest and during peak exercise of patients with suspected severe aortic stenosis and to compare flow- and pressure changes between high gradient patients and low gradient patients.

Official Title
-----------------
Pressure Gradient vs. Flow Relationships in Patients With Symptomatic Valvular Aortic Stenosis - a Comparison Between High- and Low Gradient Subtypes

Conditions
-----------------
Aortic Valve Stenosis

Intervention / Treatment
-----------------
* Procedure: Simultaneous right and left heart catheterization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with suspected severe AS scheduled for evaluation for aortic valve intervention: LVEF > 50 % AVA < 1.0 cm2 Symptomatic - at least equivalent to NYHA functional class II Exclusion Criteria: Congenital heart disease Severe coronary artery disease (main stem, proximal LAD or 3 vessel disease) Moderate or severe aortic valve regurgitation Moderate or severe mitral valve regurgitation or stenosis Moderate or severe pulmonary valve regurgitation or stenosis Moderate or severe tricuspid valve regurgitation or stenosis Severe pulmonary hypertension (tricuspid valve pressure gradient of 60 mmHg) Right ventricular dysfunction (TAPSE < 17 mm) Restrictive cardiomyopathy or cardiac amyloidosis Constrictive pericarditis Inability to perform supine bicycle exercise

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Severe aortic valve stenosis<br> | Procedure: Simultaneous right and left heart catheterization<br>* Pressure recordings across the aortic valve with simultaneous flow measurements by right heart catheterization, during rest and during supine exercise.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pressure and flow relationships across the aortic valve during rest and during supine exercise | Pressure drop across the aortic valve measured invasively. Flow across the valve estimated by right heart catheterization in the absence of aortic valve regurgitation. | 2 hours |